Medicamen Organics Limited — Updates, 09-01-2025: Press Release

Medicamen Organics Limited has raised ₹3 Cr via the issuance of 4,65,910 convertible warrants on a preferential basis to the promoter group, pricing each warrant at ₹64.39. The funds will strengthen the company's working capital and support its operational needs, reflecting a strategic move to enhance growth. Consequently, the promoters' stake in the company will increase to 61.24% from 59.69%. This capital infusion aligns with Medicamen’s ongoing projects and growth strategy, aiming to bolster its capacity to meet rising market demands. Managing Director Mr. Bal Kishan Gupta emphasized that this funding will accelerate project execution and contribute to the company’s commitment to delivering stakeholder value. Overall, this initiative positions Medicamen Organics favorably within the competitive pharmaceutical landscape, warranting close attention from investors.